AbbVie's $10.9B Apogee Bet; UnitedHealth Covers Guardant

AbbVie ($ABBV) completed its $10.9B acquisition of Apogee Therapeutics, strengthening its immunology portfolio beyond Humira with the addition of Zumilokibart optionality. Analysts view the deal as widening AbbVie's competitive moat in the post-Humira era. $ABBV also delivered topline Phase 3 CLL14 trial data at the European Hematology Association Congress, affirming venetoclax's enduring safety and efficacy in untreated chronic lymphocytic leukemia. Merck ($MRK) discontinued an investigational Alzheimer's drug trial under its Neuphoria partnership, citing business reasons, leading to declines in both $MRK and partner Neuphoria. Johnson & Johnson ($JNJ) announced it will not enter the obesity drug market, focusing instead on cancer and neuroscience as viable areas for long-term growth.

Guardant Health ($GH) announced that UnitedHealth Group ($UNH) will now cover its Shield blood test for colorectal cancer screening, making it the first major commercial insurer to provide coverage for adults aged 45 or older. The coverage decision comes amid rising CRC rates for adults under 65 and mortality trends showing colorectal cancer as the leading cause of cancer death for those under 50. Multi-cancer early detection tests are finding their way into medical practices, with Grail awaiting an FDA ruling on its cancer screening test. DexCom ($DXCM) faces disruption from GLP-1 drugs as it targets non-insulin Type 2 diabetes continuous glucose monitoring growth, with analysts noting the company's growth thesis still needs to be proven.

Intuitive Surgical ($ISRG) has declined more than 29% over the past six months and is now trading close to its 52-week lows, according to analyst commentary. The downward pressure stems from regulatory scrutiny regarding instrument reuse and concerns over Chinese competition, though analysts expect the stock to rebound based on their 12-month average price targets. The robotics industry is experiencing transformation driven by advancements in artificial intelligence, automation, and machine learning in 2026. Johnson & Johnson ($JNJ) launched its Dual Energy THERMOCOOL SMARTTOUCH SF Platform commercially in Europe on June 25, making it available to electrophysiologists across the EMEA region for cardiac ablation treatment.

Eli Lilly ($LLY) released additional details on June 25 about its Medicare GLP-1 Bridge program, explaining how eligible Medicare Part D patients can access its two weight management drugs for a flat $50 per month copay. Analysts set a price target of $1,349.37 for $LLY, pointing to 12.5% upside from a recent price of $1,199.43, rating the stock a buy with a 90% confidence score. The GLP-1 franchise is compounding faster than the market appreciated, and Foundayo has opened a scalable oral channel to expand access.

Bristol-Myers Squibb ($BMY) announced a clinical trial collaboration and supply agreement with Arcus Biosciences on June 3, where Arcus's investigational kidney cancer drug, casdatifan, will be added to Bristol-Myers's ongoing Phase 1/2 ROSETTA RCC-208 trial. Abbott Laboratories ($ABT) saw the U.S. Department of Justice close its criminal investigation into the company's Michigan baby formula plant, though authorities are pursuing civil penalties tied to alleged manufacturing failures that contributed to a national baby formula shortage. Baird initiated coverage of $ABT with an Outperform rating and a $121 price target, citing the company's diversified portfolio and upcoming product launches as positioning it for stronger earnings growth despite near-term headwinds.

Investor focus will turn to continued payer coverage decisions for multi-cancer early detection tests as Grail awaits FDA action. The obesity drug market remains a competitive battleground as $LLY expands patient access through the Medicare Bridge program while $JNJ focuses on cancer and neuroscience instead. $ISRG faces near-term headwinds from regulatory scrutiny and competitive pressures, though analysts maintain optimistic price targets. The competitive dynamics in immunology will intensify as $ABBV integrates the Apogee acquisition and $JNJ expands its cancer pipeline through the planned Firefly Bio acquisition.